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Abstract
Background Immunologists are increasingly being asked to assess patients with non-classical and secondary antibody deficiency
to determine their potential need for immunoglobulin replacement therapy (IGRT). Immunoglobulin is a limited, expensive
resource and no clear guidance exists for this broad patient group. The purpose of this survey is to establish what factors influence
the decision to commence IGRT in adult patients, when diagnostic criteria for primary antibody deficiency are not fulfilled.
Methods Under the auspices of the United Kingdom Primary Immunodeficiency Network (UKPIN), a study group was
established which circulated an online questionnaire to the consultant body across the UK and Ireland. Results provided a
snapshot of the current clinical practice of 71% of consultant immunologists, from 30 centers.
Results In order of importance, factors which influence the decision to commence IGRT include number of hospital admissions with
infection, serum IgG level, bronchiectasis, radiologically proven pneumonia, number of positive sputum cultures, number of antibiotic
courses, and results of immunization studies. The commonest test vaccine used was Pneumovax 23 with measurement of serotype-
specific responses at 4 weeks, with a threshold of 0.35 μg/ml in 2/3 of serotypes measured. Eighty-six percent of patients are treated
with a trial of prophylactic antibiotics prior to consideration of IGRT. Efficacy of IGRT trial is assessed at between 6 and 12 months.
Conclusions There was consistency in clinical practice using a combination of clinical history, evidence of infections, and
vaccination testing for diagnosis. However, there was some variation in the implementation of this practice, particularly in
vaccine choice and assessment of response to vaccination.
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Background
Immunoglobulin replacement therapy (IGRT) is a mainstay in
the management of patients with antibody deficiency [1, 2].
IGRT is delivered either by the intravenous (IVIG) or subcu-
taneous (SCIG) routes either in hospital or at home. Antibody
deficiency can be primary (PID) or secondary (SID) to an
underlying disorder, such as chronic lymphocytic leukaemia
or immunosuppressive treatment. The diagnosis of antibody
deficiency can be clear-cut, as in X linked agammaglobulin-
emia, where there is a complete absence of antibodies and B
cells. However, more often, the diagnosis is less explicit and
immunologists use a combination of clinical history and lab-
oratory investigation including test vaccination and serologi-
cal testing to make a diagnosis [3]. The absence of a single
laboratory or clinical parameter to predict response to IGRT is
challenging, and in practice, this is usually assessed using a
combination of clinical response and serum IgG level.
Therapeutic immunoglobulin is a limited, relatively expensive
resource, and in the past, there have been intermittent interrup-
tions of supply because of occasional manufacturing difficulty or
quality control failures. It is therefore imperative that immuno-
globulin is used carefully, and to this end in 2008, the
Department of Health (DoH, England and Wales) introduced
clinical guidance on the use of IGRT, which covers approved
indications, recommended dosing, and monitoring. This guid-
ance, updated in 2012, (https://www.gov.uk/government/
publications/clinical-guidelines-for-immunoglobulin-use-
second-edition-update) includes a colour-coded classification to
prioritise immunoglobulin prescription across all specialities for a
wide range of conditions including IGRT and immunomodula-
tory usage. These guidelines are based on the strength of evi-
dence, expert opinion, and the availability of alternative therapies
for these medical conditions. Based on this classification, DoH
approval for the use of IGRT is automatically granted (red),
approved when supply is not compromised (blue), granted if
alternate therapy unavailable or ineffective (grey), and not nor-
mally granted (black). Hospitals and regions have established
immunoglobulin advisory panels (IAP) which include represen-
tatives of relevant clinical specialities, pharmacy, and commis-
sioner stakeholders, to ensure that the guidance is fully imple-
mented. A national immunoglobulin registry is also established
to collect data on usage nationally.
The purpose of this survey is to establish what factors most
influence colleagues to commence IGRT in adult patients, when
strict diagnostic criteria for CVID, XLA, and other well-defined
PIDs are not fulfilled. Definition of this patient group is chal-
lenging, but would include patients with a > 2SD reduction in a
single class of immunoglobulin (IgG/IgA or IgM), IgA or IgG
subclass deficiency accompanied by impaired responses to im-
munization and a history of recurrent sinopulmonary infection.
In the DoH guidance, primary antibody deficiency (including
specific antibody deficiency) is classified as a red indication.
Criteria for the diagnosis of specific antibody deficiency
(SPAD) are not defined but the guidelines state the diagnosis
must be established by a clinical immunologist. SID due to any
cause is recognized as a blue indication. The SID diagnostic
criteria are more specific and require a history of infections in
the presence of hypogammaglobulinaemia, failure to respond to
polysaccharide vaccine challenge, and a lack of response to a 3-
month course of prophylactic antibiotics.
In general, lower serum IgG concentrations are associated
with an increased risk of infection. However, serum IgG alone
is not a definitive biomarker. Patients may have very low IgG
levels but not suffer from infections, or patients with normal IgG
levels may demonstrate susceptibility to severe or recurrent in-
fection and may be diagnosed with specific antibody deficiency
(SPAD). SPAD is characterised as a failure to respond normally
to test immunizationwith a polysaccharide vaccine in the context
of a normal total level of IgG [4]. There is however, no consensus
as to what constitutes a Bnormal^ response to polysaccharide
immunization. In addition, normal range responses in patients
with co-morbidities has not been well established [5]. It is also
widely recognised that inter-assay variability may be consider-
able such that individual laboratories should establish Bnormal^
range responses for polysaccharide antibody assays [6, 7].
Despite this uncertainty, in the UK, SPAD qualifies as a red
indication under the DoH approval guidelines, which effectively
allows automatic approval of IGRT.
The detail of what constitutes a significant infection history,
what defines a low IgG level, which vaccine or prophylactic
antibiotic to use, and when and how tomeasure the response to
vaccination or treatment is not prescribed, and so the diagnosis
of SPAD remains at the discretion of a clinical immunologist.
This lack of diagnostic certainty leads to differing opinions
and there is likely to be some variation in practice across dif-
ferent centers. To address this, a UKPIN audit steering group
was assembled to undertake a survey of UK and Irish consul-
tant immunologists to establish current practice in relation to
the decision to commence IGRT in their practice.
Methods
The steering group was formed from the immunology consultant
body. As this project was an audit of practice, rather than re-
search, ethical approval was not required. An online question-
naire was developed on the Survey Monkey platform
(SurveyMonkey Inc., San Mateo, CA, USA www.
surveymonkey.com: appendix 1) and following approval from
the steering group, it was circulated by email to the UK and
Ireland Immunology consultant body via the UK Primary
Immunodeficiency Network (UKPIN) circulation list, and a sec-
ond consultant membership list called Travellers. In total, 59
potentially eligible consultants were identified.
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Presentation of Data
Results are largely reported as descriptive statistics and no
formal statistical comparisons or analyses are made. In some
questions, respondents were asked to rank certain factors in
order of priority and this generated Branking scores^ for each
answer choice. The answer choice with the highest average
ranking is the most preferred choice. The average ranking was
calculated by the Survey Monkey platform as follows: w =
weight of ranked position, y = response count for answer
choice. Rank score = y1w1 + y2w2 + y3w3... ynwn. Weights
were applied in reverse. In other words, the respondent’s most
preferred choice (which they rank as #1) had the highest
weight and their least preferred choice (which they ranked in
the last position) had a weight of 1. For example, if a ranking
question has five answer choices, weights were assigned as
follows: the #1 choice had a weight of 5, the #2 choice had a
weight of 4, the #3 choice had a weight of 3, the #4 choice had
a weight of 2, and the #5 choice had a weight of 1. Any N/A
responses did not factor into the average ranking.
Results
Fifty-seven individuals opened the email and 42 consultant
immunologists from the UK and Republic of Ireland responded
to the survey. This represents 71% of practicing consultant im-
munologists in the UK and Ireland with a cumulative total of
480 years of consultant experience (mean 11.42 years). Data
were collected from 30 separate centers in three of the four
countries of the UK (England (n = 33), Scotland (n = 3),
Northern Ireland (n = 3), and the Republic of Ireland (n = 2).
One response was anonymous. The survey reveals that UK
immunologists are regularly being asked to consider IGRT in
patients referred to the outpatient clinic (Table 1) with primary
and secondary antibody deficiency. 29.3% of immunologists
undertake test immunization in all patients and the remaining
70.7% undertake this in the majority of cases.
Pneumococcal Vaccination
Pneumococcal vaccination was anticipated to be the most
widely used vaccine so further questions were asked to eluci-
date UK practice (Table 2). Pneumococcal polysaccharide
vaccine, 23-valent (PPV23) was found to be the commonest
vaccine used to examine immune responses (95.2%) although
HiB (used by 71.4%), tetanus (73.8%) and Prevenar13
(73.8%) were frequently used.
Test responses were unanimously examined at 4 weeks
(with some flexibility noted from free text comments).
Vaccine responses were most commonly measured by pneu-
mococcal serotype-specific antibody (PSSA) responses by
bead-based assays or ELISA, but the survey numbers suggest
that many immunologists use both this and a whole pneumo-
coccal assay. When PSSA is used, most use a cut-off concen-
tration of 0.35 μg/ml. An adequate response is considered by
the majority of users to be achieved when > 66% of serotypes
are in the protective range, regardless of the cut-off concen-
tration. Immunologists predominantly use pneumococcal an-
tibody testing to assess B cell function as a complementary
tool to support clinical assessment but would not regard this as
a definitive diagnostic test.
Table 1 Survey of UK and Irish
Immunologists in relation to
referral and assessment of patients
with suspected nonclassical or
secondary immunodeficiency
Question 1 Answers N (%)
1. How often do you see patients as described above,
in whom you are asked to consider immunoglobulin
replacement therapy (IGRT)?
Almost every clinic 25 (59.5)
Quite often 16 (38.1)
Occasionally 1 (2.4)
Rarely 0 (0)
2. Do you see referrals from other specialties (e.g.
haematology, rheumatology) with suspected
secondary antibody deficiency related to disease
or drug therapy?
Almost every clinic 18 (42.86)
Quite often 20 (47.62)
Occasionally 3 (7.1)
Rarely 1 (2.4)
3. In assessing immune function, prior to commencing
IGRT do you undertake test immunisation?
In all patients 12 (29.3)
In the majority of patients 29 (70.7)
4. If undertaking test immunisation, which of the
following vaccines do you regularly use?
Pneumococcal Polysaccharide
Vaccine, 23-Valent (PPV23)
40 (95.2)
Meningitis ACWY conjugated 2 (4.8)
Prevenar 13 24 (57.1)
Tetanus toxoid (combined vaccine) 31 (73.8)
Haemophilus Influenza B (HiB) 30 (71.4)
Salmonella Typhi Vi 4 (9.5)
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Decision Criteria to Commence IGRT
The survey aimed to understand the factors that influenced
the decision to commence IGRT. These factors were then
ranked by the responders from most to least important
(Question 11: Table 3).
The results show that no single criterion is used but a com-
bination of significant infection; low immunoglobulin and ev-
idence of end organ damage are considered by responders the
most important.
Given the importance of clinical assessment in commenc-
ing patients on IGRT, radiological practice was also consid-
ered. Responses to question 12 indicated that high-resolution
CT scanning is routinely undertaken at initial assessment by
34 (87.2%) of respondents (all cases by n = 11 (28.2%);
majority of cases by n = 23 (59.0%)). HRCT scanning was
restricted to those cases where a daily productive cough sug-
gests the presence of bronchiectasis by n = 4 (10.3%) and only
rarely by n = 1 (2.6%).
Use of Prophylactic Antibiotics (Questions 13 and 14)
Prophylactic antibiotic prescribing prior to commencing
IGRT was also commonly implemented: prescribed in all pa-
tients by n = 9 (21.4%) immunologists, in the majority of pa-
tients by n = 27 (64.3%), in a minority of patients by n = 5
(11.9%), rarely n = 1 (2.4%), and never by n = 0 (0.0%).
The first choice of antibiotic varied between consultants
with the commonest being azithromycin followed by doxycy-
cline and amoxicillin (Table 4).
Table 2 Survey to elucidate UK
practice about pneumococcal
vaccination
Question Answer options N (%)
5. If you use both Prevenar 13 and Pneumococcal
Polysaccharide Vaccine, 23-Valent (PPV23). In
which order do you administer these?
• PPV23 first then Prevenar 13 26 (68.4)
• Prevenar 13 first then PPV23 3 (7.9)
• No fixed order 0 (0)
• Administer both simultaneously 0 (0)
• Other 9 (23.7)
6. How long after immunisation do you recommend
Bpost vaccination samples^ be taken?
• 4 weeks 42 (100)
7. In assessment of pneumococcal antibody responses,
which methodology do you use?
• Total IgG anti-pneumococcal antibody 22 (52.4)
• Total IgG2 anti pneumococcal antibody 4 (9.5)
• pneumococcal serotype specific
antibody (PSSA) (ELISA)
8 (19.0)
• PSSA (bead based assay) 32 (76.2)
8. In interpretation of PSSA results, which Bcut-off^
levels do you use?
• 0.35 mcg/ml 31(79.5)
• 0.5 mcg/ml 0 (0)
• 1.3 mcg/ml 0 (0)
• A combination of the above 8 (20.5)
9. When interpreting PSSA results, what percentage
of serotypes do you expect to exceed your chosen
Bcut-off^ in a normal response (choose the %
threshold closest to your current practice)
For 0.35 mcg/ml (35 responders)
30% of serotypes protected 0 (0.0)
50% of serotypes protected 8 (22.8)
66% of serotypes protected 24 (68.6)
90% of serotypes protected 3 (8.6)
For 1.3 mcg/ml (8 responders)
30% of serotypes protected 3 (37.5)
50% of serotypes protected 1 (12.5)
66% of serotypes protected 3 (37.5)
90% of serotypes protected 1 (12.5)
10. How do you regard the value of pneumococcal
antibody response testing in the decision to
commence IGRT?
• I regard this as a definitive diagnostic
test
0 (0.0)
• I rely on this in the majority of cases 6 (14.6)
• I rely on this to support my clinical
assessment
28 (68.3)
• I rely on this, unless it appears to
conflict with the clinical history
4 (9.8)
• I am sceptical of the value and disregard
this in some cases
3 (7.3)
• I quite often disregard this 0 (0)
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Importantly, responses to question 15 (not shown: If a pa-
tient fails to improve on a trial of prophylactic antibiotics, do
you consider a trial of IGRT?) indicated that all immunolo-
gists would consider a trial of IGRT in at a least some patients
who fail to improve on a trial of prophylactic antibiotics: re-
sponses: in all patients n = 2 (4.8%), in the majority of patients
n = 34 (81.0%), and in a minority of patients n = 6 (14.3%).
The responses to question 16 (not shown:What initial dose of
IGRT do you use?) indicate a dichotomy of approach in terms of
immunoglobulin dosing. Twenty-two over forty-two (52%) re-
spondents commence all patients on 400 mg/kg/month. In 19/42
(45%) however, the presence of bronchiectasis dictates a higher
starting dose of 600mg/kg/month.One respondent (2.5%) used a
dose of 200 mg/kg/month and 400 mg/kg/month for patients in
the same situations. Two respondents also commented they
would use a higher starting dose if the patient had bad gastroin-
testinal or other autoimmune disease.
Responses to question 17 (not shown:After what time interval
would you usually assess response to immunoglobulin replace-
ment therapy to determine whether it should be continued?) in-
dicated that immunologists use a therapeutic trial period to assess
response to immunoglobulin replacement therapy before com-
mitting to lifelong therapy. The minimum interval used was
6 months (n = 13, 31.7%), two respondents (4.9%) used a
9 month window, whereas the most common time period was
12 months with 26 (63.4%) favouring this choice.
The factors that most influenced immunologists to consider
the trial to have been successful were reduction in frequency
of reported infection, hospital admission, and antibiotic pre-
scriptions (Table 5).
We found no identifiable regional differences in responses
by location (England, Scotland, Northern Ireland, and
Republic of Ireland). Nor did free text comments indicate
any region/nation specific differences in practice.
Discussion
Primary antibody deficiencies have a prevalence of 2.11/
100,000 in the UK [8] The increased survival from cancer and
use of immunosuppressive agents in auto-inflammatory condi-
tions and transplantation is causing an increasing, but poorly
quantified burden of secondary immunodeficiency [9, 10].
The results of this survey represent the practice of the major-
ity of consultant immunologists currently practicing in the UK
and Ireland (71%), with a cumulative total of 435 years of con-
sultant experience. This is to our knowledge the first supra na-
tional survey of current clinical practice in this area. This survey
confirms that UK clinical immunologists are frequently asked to
evaluate patients, with suspected antibody deficiency, to consid-
er commencement of IGRT. Results show that there is consis-
tency in using a combination of clinical history, evidence of
infections, and vaccination testing for diagnosis. However, there
is variation in the implementation of this practice, particularly in
vaccine choice and assessment of response to vaccination.
Table 3 Ranking of factors that influenced the decision to commence
IGRT
Q.11. How do you rank the following factors in influencing your decision
to commence IGRT?
Criteria Rank score
Number of hospital admissions with infection 11.36
Total serum IgG level 10.38
Presence of bronchiectasis 10.07
Radiologically proven pneumonia 9.90
Number of positive sputum cultures 9.02
Number of courses of antibiotics (GP or pharmacy
confirmed)
8.72
Results of Immunisation studies 8.33
Types of bacteria isolated in sputum 8.05
Failure to improve on antibiotic prophylaxis 7.38
Number of self-reported chest/sinus/ear infections 6.99
Number of courses of antibiotics (patient reported) 6.64
Other structural lung disease 4.32
Self-reported Bwell-being^ 2.95
Formal quality of life assessment (including validated
questionnaires, visual analogue scales etc.)
2.87
Table 4 Ranking of
antibiotics as suitable for
prophylaxis in a patient
group
Q 14. How would you rank the following
antibiotics as suitable for prophylaxis in
this patient group?
Antibiotic Ranking score
Azithromycin 7.36
Doxycycline 6.12
Amoxicillin 6.05
Co-trimoxazole 5.11
Co-amoxiclav 4.42
Ciprofloxacin 3.18
Cefalexin 2.88
Penicillin 2.80
Table 5 The factors that most influenced immunologists to consider
the trial to have been successful
Factor Ranking score
Reduction in frequency of reported infections 5.98
Reduction in hospital admissions 5.93
Reduction in antibiotic prescription frequency 5.65
Trough/random IgG levels 3.72
Improvement in self-reported well-being 3.31
Formal quality of life assessment 3.00
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All respondents always or usually undertook immunization
studies and recommended a 4-week interval between pre- and
post-immunization samples. As expected, polysaccharide pneu-
mococcal vaccination was most commonly used, as SPAD is
defined as a failure to respond to polysaccharide vaccination.
An additional conjugate pneumococcal vaccine is advised by
many immunologists to provide enhanced therapeutic benefit.
There is some variation in how vaccine responses are
assessed including which assay to use or whether to measure
combined or individual pneumococcal serotype responses.
Whole pneumococcal assays usually assess the total IgG reac-
tive against 23 serotypes present in the pneumococcal polysac-
charide vaccine, 23-valent (PPV23) vaccine. Less than 10% of
immunologists use IgG2 subclass assays. The advantage of the
whole pneumococcal assay is that the test is relatively inexpen-
sive and there is a single value output. However, these tests do
not identify abnormal responses to individual serotypes and
may therefore be falsely reassuring [11]. Furthermore, there is
no correlation in the results obtained by whole pneumococcal
ELISA, and measuring antibody levels to individual pneumo-
coccal serotypes [11]. In contrast, bead-based or ELISA
methods that assess serotype-specific IgG concentrations do
provide this detail. However, this additional data poses chal-
lenges in interpretation both in defining the percentage of sero-
types that would be expected to elicit an antibody response and
the threshold level for protection against invasive and non-
invasive pneumococcal disease (IPD, n-IPD, respectively) [12].
An IPD protective level of 0.35 μg/ml was proposed by the
WHO following collation of three large conjugate vaccine
studies in neonates. A much higher nIPD protective level of
1.3 μg/ml was proposed following analysis of US data using
PPV23. A further consideration is that it is likely that not all
serotype-specific antibodies are equally protective and there-
fore simply counting the percentage response may bemislead-
ing. It can further be argued that defining a protective level is
irrelevant to the diagnosis of immunodeficiency. The aim of
vaccination studies here is simply to differentiate an abnormal
from a normal immune response. In the absence of definitive
evidence, this survey reveals that the majority opinion in the
UK is to use 0.35μg/ml in two thirds of serotypes measured as
an indicator of a Bnormal response.^ The inconsistencies in
antibody assessment methods may also explain why evalua-
tion of vaccine responses are not considered a definitive test.
It is also noteworthy that a recent study of antibody re-
sponses in patients with chronic sinusitis indicated that 11%
of healthy controls would fulfil diagnostic criteria for SPAD,
and this lack of certainty in the definition of SPAD is likely to
contribute to variation in practice [13].
Prophylactic antibiotics are used by 85% UK immunolo-
gists to reduce infection rates. The choice of antibiotic natu-
rally depends on bacterial sensitivities (where available) and
also intolerance and allergy. Prophylactic antibiotic usage can
be controversial in an era of increasing antibiotic stewardship.
However, immunoglobulin is a scarce and expensive resource
and alternative strategies should be considered.
The ranking of factors influencing the commencement of
immunoglobulin provided some of the most interesting data.
Despite intense interest in the assessment of immunization
responses as an indicator of immune function [2, 12], these
were ranked only 7th out of 14 factors that most influenced the
decision to commence IGRT. Conventional direct and indirect
clinical indicators of recurrent chest infection all ranked
higher in the decision-making hierarchy, with a bias toward
the more objective (number of proven infections, pharmacy
confirmed prescriptions, etc) compared to self-reported ill-
ness. An important finding is that self-reported Bwell-being^
and formal quality of life assessments were ranked as the least
important of all factors considered.Whilst improved quality of
life and well-being are clearly worthwhile clinical goals, they
are too non-specific and multifactorial to be used as indicators
of the need for (or response to) immunoglobulin therapy.
There was consistency in the use of baseline HRCT chest in
the assessment of patients and the majority were in favour of a
12-month trial period for IGRT (63.4% of respondents). The
identification that approximately half of colleagues use an initial
starting dose of 400 mg/kg/month for all patients whilst approx-
imately the other 50% use a higher starting dose for those with
perceived complications/end organ damage is in line with recent
recommendations ([2, 14]. Free text responses from many indi-
cated that treatment is tailored to the needs of the individual
patient. A specific question about any differences in dosage of
IgG used to treat secondary antibody deficient versus specific
antibody deficiency was not included in this survey; however,
free text comments did not indicate any difference in practice. It
therefore appears that common practice by the immunologists in
the UK and Ireland is to treat all patients considered to have an
antibody deficiency with similar IgG doses. Initial dose selection
is adjusted for complications like the presence of bronchiectasis
by 45% of respondents.
The ranking of factors used to judge success of a trial of
IGRTwas not surprisingly focused on reduction in number of
infections, hospital admissions, and numbers of prescribed
antibiotic courses. This survey did not explore the importance
of intravenous (IV) versus oral antibiotics prior usage in the
decision-making. A previous paediatric study found that prior
usage of IV antibiotics was a predictor of neutrophil PID in
particular [15], and this may be an issue worthy of future
investigation in non-classical or SID.
This survey provides a valuable snapshot of the current prac-
tice of immunologists in the UK and Ireland in how they ap-
proach the decision to treat adults with non-classical PID or
suspected SID with IGRT. SID has clear diagnostic criteria in
terms of a serum IgG< 5 g/L accompanied by failure to respond
to polysaccharide vaccine challenge. In PID, in addition to im-
munoglobulin deficiencies, one of the accepted criteria is a spe-
cific antibody deficiency. However, the diagnosis of SPAD is
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based on the sole immunological criterion of failure to respond to
polysaccharide vaccine challenge that can be identified using a
variety of methodologies and interpretation choices. The vac-
cines used to assess B cell function coupled with differing defi-
nitions of what constitutes a Bnormal^ response to test immuni-
zation with pneumococcal vaccines suggests that eligibility
criteria for IGRT in SPAD are likely to be subject to substantial
variation and attract controversy [14].
The outcomes demonstrate that the decision-making pro-
cess is multifactorial and complex, and some factors are not
mutually exclusive. There is no single universally accepted
biomarker to predict clinically significant antibody deficiency;
in addition to laboratory test results, most UK and Irish im-
munologists rely heavily on the clinical presentation of a pa-
tient to identify those who may require long term IGRT.
Take Home Messages
& Immunologists frequently see patients who do not fulfil
classical definitions of PID for the assessment of suitabil-
ity for IGRT
& Test immunisation with pneumococcal vaccines is widely
used however there is variability on assessing a “ normal “
response
& Whilst all clinicians use test immunisation in their assess-
ment, most do not regard this as a definitive diagnostic test
. Objective clinical indicators of frequency and severity of
infection tend to take precedence over immunisation stud-
ies in determining the need for IGRT
& Prophylactic antibiotics are commonly used as a precursor
to IGRT
& Immunologists in the UK and Ireland commonly use a
“trial of IGRT” usually for 12 months ( 63.4% of respon-
dents) to assess its clinical efficacy in individual patients
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Appendix 1
Immunoglobulin decision to treat?
Introduction.
The decision as to whether individual patients require im-
munoglobulin replacement therapy (IGRT) is not always easy
to address. Multiple factors come into play including assess-
ment of patient well-being, co-morbidity and laboratory test-
ing. Guidance in this area is not absolute and UKPIN is keen
to determine the views and cumulative experience of the con-
sultant body in the UK.
The purpose of this survey is to establish what factors most
influence colleagues to commence IGRT in adult patients,
when strict diagnostic criteria for CVID, XLA, and other
well-defined PIDs are not fulfilled. Definition of this patient
group is challenging, but would include patients with slightly
low total serum IgG, M or A levels, IgA or IgG subclass
deficiency, or impaired responses to immunization. We are
also interested in your approach to patients suspected of sec-
ondary antibody deficiency following drug therapy or haema-
tological disorders.
The survey is neither a test of knowledge of current guide-
lines, nor the relative merit of different laboratory systems, but
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simply an attempt to delineate current practice across the UK
by consultant immunologists looking after adult (> 18 year
old) patients suspected of primary or secondary antibody de-
ficiency. It is expected that there will be variations in practice
across the countries, and if that is confirmed, that will be of
value in informing our practice.
All data will be treated confidentially; however, it is hoped
that the individual/center anonymised data will merit submis-
sion for publication; however, data submission will only occur
with the consent and acknowledgment of all contributors.
Thank you in advance for your participation.
1. How often do you see patients as described above, in
whom you are asked to consider immunoglobulin re-
placement therapy (IGRT)?
Almost every clinic
Quite often
Occasionally
Rarely
Other (please specify)
2. Do you see referrals from other specialties (e.g.
haematology, rheumatology) with suspected secondary
antibody deficiency related to disease or drug therapy?
Almost every clinic
Quite often
Occasionally
Rarely
Other (please specify)
3. In assessing immune function, prior to commencing
IGRT do you undertake test immunisation?
In all patients
In the majority of patients
In a minority of patients
Rarely
Never
Any Comments?
4. If undertaking test immunisation, which of the following
vaccines do you regularly use?
Pneumococcal capsular polysaccharide (Pneumovax
II or generic)
Meningitis ACWY conjugated
Prevenar 13
Tetanus toxoid (in combined vaccine)
Haemophilus Influenza B (HiB)
Salmonella Typhi Vi
Other (please specify)
5. If you use both Prevenar 13 and Pneumovax II. In which
order do you administer these?
Pneumovax II first then Prevenar 13
Prevenar 13 first then Pneumovax II
No fixed order
Administer both simultaneously
Other (please specify)
6. How long after immunisation do you recommend Bpost
vaccination samples^ be taken?
2 weeks
4 weeks
8 weeks
no fixed interval
Other (please specify)
7. In assessment of pneumococcal antibody responses,
which methodology do you use?
Total IgG anti-pneumococcal antibody
Total IgG2 anti pneumococcal antibody
Pneumococcal serotype specific antibodies (ELISA)
Pneumococcal serotype specific antibodies (bead
based assay)
Other (please specify)
8. In interpretation of pneumococcal serotype specific anti-
body (PSSA) results, which Bcut-off^ levels do you use?
0.35 mcg/ml
0.5 mcg/ml
1.3 mcg/ml
A combination of the above
Other (please specify)
9. What percentage of serotypes do you expect to exceed
your chosen Bcut-off^ in a normal response (choose the
%threshold closest to your current practice)?
10. How do you regard the value of pneumococcal antibody
response testing in the decision to commence IGRT?
I regard this as a definitive diagnostic test
I rely on this in the majority of cases
I rely on this to support my clinical assessment
I rely on this, unless it appears to conflict with the
clinical history
I am sceptical of the value and disregard this in some
cases
I quite often disregard this
Other (please specify)
> 0.35 mcg/ml > 0.5 mcg/ml > 1.3 mcg/ml 
30% 
50% 
66% 
90% 
not applicable 
Other (please specify) 
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11. How do you rank the following factors in influencing
your decision to commence IGRT (1=most important,
14 = least important)?
Number of self-reported chest/sinus/ear infections
Number of courses of antibiotics (patient reported)
Number of courses of antibiotics (GP or pharmacy
confirmed)
Number of hospital admissions with infection
Number of positive sputum cultures
Types of bacteria isolated in sputum
Radiologically proven pneumonia
Presence of bronchiectasis
Other structural lung disease
Results of Immunisation studies
Self-reported Bwell-being^
Formal quality of life assessment (including validated
questionairs, visual analogue scales etc)
Total serum IgG level
Failure to improve on antibiotic prophylaxis
12. In assessing patients for possible immunoglobulin re-
placement therapy, do you undertake a high resolution
CT scan of chest?
In all cases at initial assessment
In the majority of cases at initial assessment
Only in those cases where a daily productive cough
suggests the presence of bronchiectasis
Only in those cases where immunological investiga-
tion in inconclusive.
Rarely.
Other (please specify)
13. Prior to commencing IGRT in this group, do you pre-
scribe prophylactic antibiotics?
In all patients
In the majority of patients
In a minority of patients
Rarely
Never
Other (please specify)
14. How would you rank the following antibiotics as suitable
for prophylaxis in this patient group (1= most suitable)?
amoxicillin
azithromycin
ciprofloxacin
co-amoxiclav
cefalexin
co-trimoxazole
doxycyclin
penicillin
15. If a patient fails to improve on a trial of prophylactic
antibiotics, do you consider a trial of IGRT?
In all patients
In the majority of patients
In a minority of patients
rarely
never
16. What initial dose of IGRT do you use?
17. After what time interval would you usually assess re-
sponse to immunoglobulin replacement therapy to deter-
mine whether it should be continued?
3 months
6 months
9 months
12 months
18 months
24 months
Other (please specify)
18. How do you rank these factors in assessing a successful
response to IGRT (1 = most important, 7 = least impor-
tant)?
Trough/random serum IgG levels
Reduction in frequency of reported infections
Reduction in antibiotic prescription frequency
Reduction in hospital admissions
Improvement in self-reported well being
Formal quality of life assessment (standardised ques-
tionnaire, visual analogue scale etc)
Other
19. Please provide the following details about yourself
Name
Centre
Year of Consultant Appointment
Any additional comments you would like to make?
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In all patients 
In patients with no 
bronchiectasis 
In patients with 
bronchiectasis 
In patients with 
other features 
 (please define 
below) 
200 mg/kg/month 
400 mg/kg/month 
600 mg/kg/month 
800 mg/kg/month 
Other (please specify) 
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